Parexel, JFCR ink agreement to accelerate access to oncology clinical trials in Japan
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, has announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
Under the agreement, JFCR will join Parexel’s Global Site Alliance network, making it a preferred site for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research. Parexel will leverage JFCR’s expertise to help sponsors develop protocols that better align with Japan’s standard of care and regulatory approval processes — resulting in streamlined patient recruitment and study start-up.
“Consistent with global trends, the incidence of cancer is expected to increase in Japan. We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients,” said Shigehiro Miki, Corporate Vice President and General Manager, Parexel, Japan.
“With experience spanning more than 115 years, JFCR is Japan’s first and largest medical organization dedicated to cancer care. The organization is known for its cross-functional, holistic cancer centre, state-of-the-art research facilities and extensive number of patients under their care. JFCR’s therapeutic expertise in combination with Parexel’s clinical research experience will enable both organizations to efficiently recruit Japanese patients often underrepresented in oncology research while expanding cancer care options in Japan.
“Parexel and JFCR enter into this strategic alliance driven by a shared sense of urgency to enable sponsors to conduct trials in Japan and ensure these patients have access to innovative clinical research. To improve well-being of people worldwide by conquering cancer is the fundamental principle of JFCR. We look forward to collaborating closely with Parexel to realize our principle,” said Dr Takeshi Sano, Hospital Director, Cancer Institute Hospital of JFCR.
Parexel’s Site Alliance Network is designed to provide a strategic, site solutions approach to address critical challenges in the clinical trial pathway, recruit patients more efficiently and expand clinical trial opportunities to investigators and patients globally. The network consists of more than 480+ sites representing approximately 21,000 investigators worldwide.
The company’s strategic alliance agreement with JFCR is an extension of its Patients-First focus and efforts to drive clinical innovation in key therapeutic areas, such as oncology, in the Asia/Pacific region. Parexel maintains relationships with other leading alliance sites in the region, including Kyoto University Hospital, Osaka International Cancer Institute, Beijing Illness Challenge Foundation and the Cancer Hospital Chinese Academy of Medical Sciences.
Source : 1
AuroBlog | Clinical Research Blog | Aurous HealthCare CRO, India 